NO20011211D0 - Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme - Google Patents

Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme

Info

Publication number
NO20011211D0
NO20011211D0 NO20011211A NO20011211A NO20011211D0 NO 20011211 D0 NO20011211 D0 NO 20011211D0 NO 20011211 A NO20011211 A NO 20011211A NO 20011211 A NO20011211 A NO 20011211A NO 20011211 D0 NO20011211 D0 NO 20011211D0
Authority
NO
Norway
Prior art keywords
preparation
methods
same
pharmaceutical preparations
multiple unit
Prior art date
Application number
NO20011211A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011211L (no
Inventor
Venkata-Rangarao Kanikanti
Roland Rupp Haferbusch
Erich Brendel
Claus Weisemann
Ernst Chantraine
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20011211L publication Critical patent/NO20011211L/no
Publication of NO20011211D0 publication Critical patent/NO20011211D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Nonmetallic Welding Materials (AREA)
NO20011211A 1998-09-18 2001-03-09 Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme NO20011211D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19842753A DE19842753A1 (de) 1998-09-18 1998-09-18 Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
PCT/EP1999/006882 WO2000016748A1 (de) 1998-09-18 1999-09-17 Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
NO20011211L NO20011211L (no) 2001-03-09
NO20011211D0 true NO20011211D0 (no) 2001-03-09

Family

ID=7881376

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011211A NO20011211D0 (no) 1998-09-18 2001-03-09 Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme

Country Status (29)

Country Link
US (1) US6805881B1 (et)
EP (1) EP1113787B1 (et)
JP (1) JP2002526437A (et)
KR (1) KR100660072B1 (et)
CN (1) CN1178650C (et)
AT (1) ATE260645T1 (et)
AU (2) AU5861499A (et)
BG (1) BG105325A (et)
BR (1) BR9913839A (et)
CA (1) CA2344372C (et)
DE (2) DE19842753A1 (et)
DK (1) DK1113787T3 (et)
EE (1) EE04700B1 (et)
ES (1) ES2215404T3 (et)
HK (1) HK1040932B (et)
HR (1) HRP20010198A2 (et)
HU (1) HUP0103669A3 (et)
ID (1) ID28735A (et)
IL (2) IL141532A0 (et)
NO (1) NO20011211D0 (et)
NZ (1) NZ510563A (et)
PL (1) PL195543B1 (et)
PT (1) PT1113787E (et)
RU (1) RU2235540C2 (et)
SK (1) SK285099B6 (et)
TR (1) TR200100756T2 (et)
UA (1) UA73097C2 (et)
WO (2) WO2000016747A1 (et)
ZA (1) ZA200101485B (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005012561B4 (de) 2005-03-18 2008-06-19 Christian Beer Verfahren zum Betrieb eines Werkstück-Transfersystems
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP1934208B1 (de) 2005-10-04 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
CN100448432C (zh) * 2006-10-26 2009-01-07 徐竹青 高溶出度尼莫地平分散片的制备方法
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US7952167B2 (en) * 2007-04-27 2011-05-31 Taiwan Semiconductor Manufacturing Company, Ltd. Scribe line layout design
BRPI1007452A2 (pt) * 2009-01-28 2016-02-16 Novartis Ag formulações galênicas de compostos orgânicos
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5482525A (en) 1977-12-13 1979-06-30 Aisan Ind Co Ltd Exhaust gas recirculation system
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JPH03145418A (ja) 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2725624B1 (fr) 1994-10-14 1997-01-17 Jouveinal Inst Rech Procede de preparation de formes pharmaceutiques a liberation controlee
DE19504831A1 (de) 1995-02-14 1996-09-05 Basf Ag Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose

Also Published As

Publication number Publication date
EE200100161A (et) 2002-08-15
EP1113787A1 (de) 2001-07-11
AU5861499A (en) 2000-04-10
US6805881B1 (en) 2004-10-19
PT1113787E (pt) 2004-07-30
AU6191899A (en) 2000-04-10
ZA200101485B (en) 2002-02-22
PL346535A1 (en) 2002-02-11
SK285099B6 (sk) 2006-06-01
EE04700B1 (et) 2006-10-16
KR20010073172A (ko) 2001-07-31
NO20011211L (no) 2001-03-09
IL141532A0 (en) 2002-03-10
HK1040932B (zh) 2005-08-05
BG105325A (bg) 2001-11-30
ES2215404T3 (es) 2004-10-01
CA2344372A1 (en) 2000-03-30
CA2344372C (en) 2009-12-22
NZ510563A (en) 2002-10-25
CN1178650C (zh) 2004-12-08
KR100660072B1 (ko) 2006-12-22
ID28735A (id) 2001-06-28
CN1317959A (zh) 2001-10-17
ATE260645T1 (de) 2004-03-15
SK3722001A3 (en) 2001-10-08
EP1113787B1 (de) 2004-03-03
HUP0103669A3 (en) 2006-07-28
IL141532A (en) 2007-03-08
TR200100756T2 (tr) 2001-07-23
WO2000016747A1 (de) 2000-03-30
HRP20010198A2 (en) 2002-04-30
BR9913839A (pt) 2001-06-12
HK1040932A1 (en) 2002-06-28
AU750617B2 (en) 2002-07-25
PL195543B1 (pl) 2007-09-28
DK1113787T3 (da) 2004-05-17
HUP0103669A2 (hu) 2002-01-28
JP2002526437A (ja) 2002-08-20
DE19842753A1 (de) 2000-03-23
UA73097C2 (en) 2005-06-15
WO2000016748A1 (de) 2000-03-30
DE59908764D1 (de) 2004-04-08
RU2235540C2 (ru) 2004-09-10

Similar Documents

Publication Publication Date Title
NO20011211D0 (no) Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme
AU1227899A (en) Osmotic medicament releasing system
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
HUP0002296A2 (hu) Sertralinsók és a sertralin elnyújtott felszabadulását biztosító dózisformák
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
YU35893A (sh) Formulacije oksidona sa kontrolisanim otpuštanjem i njihova upotreba
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
CA2330480A1 (en) Controlled release formulation of divalproex sodium
HUP0202781A2 (hu) Béta-karbolin szemcsés formája, ezt tartalmazó gyógyszerkészítmények, előállításaik és alkalmazásuk
DE69508580T2 (de) Pellets
GR3018685T3 (en) Method for the manufacture of a controlled release solid unit dosage form.
ES2010466A6 (es) Formas de administracion solidas, de rapida desintegracion.
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
HUT59316A (en) Process for producing solid, orally administrable dosage forms comprising iphosphamide as active ingredient
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
CA2123332A1 (en) Controlled Release Formulation of Diltiazem Hydrochloride
ES2004693A6 (es) Un procedimiento para la preparacion de una composicion farmaceutica solida administrable por via oral, que contiene vinburnina como principio activo.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application